Interesting facts
Interesting Facts about 6-[4-(1-cyclohexyltetrazol-5-yl)butoxy]-3,4-dihydro-1H-quinolin-2-one
This intriguing compound, known for its complex structure, incorporates multiple functional groups that contribute to its unique properties and potential applications in various fields. Here are some fascinating insights:
- Drug Development: The quinolin-2-one backbone is often found in pharmaceutical research due to its biological activity. Compounds possessing this core structure have demonstrated various therapeutic effects, including anti-inflammatory, anti-cancer, and antimicrobial properties.
- Tetrazole Significance: The inclusion of a tetrazole group in the molecule enhances its bioactivity and can improve the solubility compared to other scaffolds. Tetrazoles are known for their use in drug development, leading to compounds with improved pharmacokinetic profiles.
- Cyclohexyl Moiety: The cyclohexyl group can affect the lipophilicity of the compound, potentially fostering better membrane penetration and cellular uptake. This is an essential feature in creating compounds that target cellular pathways effectively.
- Potential for Customization: The presence of the butoxy linker allows for further modifications to the molecule. By altering substituents or modifying the linker length, researchers can tailor the compound for specific biological activities or improve the effectiveness of existing drugs.
- Analog Studies: Given its structural complexity, this compound serves as an excellent candidate for analog studies. By synthesizing related compounds, scientists can evaluate structure-activity relationships, ultimately guiding the development of more potent derivatives.
As a result, the compound's intricate combination of quinolin-2-one, tetrazole, and cyclohexyl functionalities makes it a valuable subject of study in medicinal chemistry. Its potential to impact therapeutic strategies emphasizes the importance of exploring novel chemical entities in the quest for effective medications.
Synonyms
cilostazol
73963-72-1
Pletal
Cilostazole
Pletaal
OPC-13013
Cilostazolum
OPC-21
Cilostazolum [INN-Latin]
OPC 21
6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydroquinolin-2(1H)-one
CHEBI:31401
6-[4-(1-cyclohexyltetrazol-5-yl)butoxy]-3,4-dihydro-1H-quinolin-2-one
6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydro-2(1H)-quinolinone
3,4-Dihydro-6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-2(1H)-quinolinone
NSC-758936
BRN 3632107
DTXSID9045132
UNII-N7Z035406B
6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydrocarbostyril
MFCD00866780
N7Z035406B
6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone
6-[4-(1-cyclohexyl-1H-1,2,3,4-tetrazol-5-yl)butoxy]-1,2,3,4-tetrahydroquinolin-2-one
MLS000028470
DTXCID7025132
HSDB 8312
6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydroquinolin-2(1H)-one
NSC 758936
Cilostazol [USAN:USP:INN:BAN:JAN]
NCGC00015207-07
SMR000058428
Cilostazolum (INN-Latin)
2(1H)-Quinolinone, 3,4-dihydro-6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-
2(1H)-quinolinone, 6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydro-
2(1H)-Quionlinone, 6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydro-
6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-2(1H)-quinolinone
CILOSTAZOL (MART.)
CILOSTAZOL [MART.]
CILOSTAZOL (USP-RS)
CILOSTAZOL [USP-RS]
CILOSTAZOL (USP MONOGRAPH)
CILOSTAZOL [USP MONOGRAPH]
6-[4-(1-cyclohexyl-1h-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril
Cilostazol (USAN:USP:INN:BAN:JAN)
CAS-73963-72-1
Pletal (TN)
SR-01000003107
6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy)-3,4-dihydro-1H-quinolin-2-one
6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-1H-quinolin-2-one
Cilostazol,(S)
Cilostazolum (Latin)
Cilostazol (Standard)
Tocris-1692
CILOSTAZOL [MI]
Opera_ID_488
CILOSTAZOL [INN]
CILOSTAZOL [JAN]
Spectrum2_001118
Spectrum3_001170
Spectrum4_000772
Spectrum5_001762
CILOSTAZOL [USAN]
Lopac-C-0737
CILOSTAZOL [VANDF]
CHEMBL799
C 0737
CILOSTAZOL [WHO-DD]
Lopac0_000218
REGID_for_CID_2754
SCHEMBL16128
BSPBio_002759
KBioGR_001184
MLS000758281
MLS000759507
MLS001076067
MLS002153891
SPECTRUM1505230
SPBio_001256
Cilostazol (JP18/USP/INN)
GTPL7148
CILOSTAZOL [ORANGE BOOK]
KBio3_002259
BCPP000279
HMS1922N15
HMS2093M14
HMS2096F16
HMS2234C06
HMS3260L17
HMS3268O09
HMS3412B18
HMS3654J13
HMS3676B18
HMS3713F16
Pharmakon1600-01505230
BCP03724
Tox21_110098
Tox21_500218
BDBM50225508
CCG-39646
HY-17464R
NSC758936
s1294
AKOS015855512
Cilostazol, >=98% (HPLC), powder
OPC 13013; OPC 21; Pletaal
Tox21_110098_1
AC-4334
BCP9000530
CS-1759
DB01166
FC03161
KS-5154
LP00218
SDCCGSBI-0050206.P003
NCGC00015207-01
NCGC00015207-02
NCGC00015207-03
NCGC00015207-04
NCGC00015207-05
NCGC00015207-06
NCGC00015207-08
NCGC00015207-09
NCGC00015207-10
NCGC00015207-11
NCGC00015207-12
NCGC00015207-25
NCGC00022153-02
NCGC00022153-04
NCGC00022153-05
NCGC00022153-06
NCGC00022153-07
NCGC00260903-01
HY-17464
BCP0726000145
RETAL;PLETAL;OPC 21;PLETAAL;Cilostal
SBI-0050206.P002
C2587
EU-0100218
NS00009762
SW199053-2
D01896
F20538
AB00382988-14
AB00382988_15
AB00382988_16
Q258591
SR-01000003107-2
SR-01000003107-4
SR-01000003107-7
BRD-K67017579-001-04-2
BRD-K67017579-001-05-9
BRD-K67017579-001-07-5
BRD-K67017579-001-13-3
BRD-K67017579-001-17-4
BRD-K67017579-001-26-5
BRD-K67017579-001-27-3
BRD-K67017579-001-28-1
SR-01000003107-10
Z1501485368
Cilostazol, United States Pharmacopeia (USP) Reference Standard
6-[4-(1-cyclohexyl-1,2,3,4-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril
6-[4-(l-cyclohexyl-1,2,3,4-tetrazol-5-yl)butoxyl]-3,4-dihydrocarbostyril
Cilostazol, Pharmaceutical Secondary Standard; Certified Reference Material
6-(4-(1-CYCLOHEXYL-1H-TETRAZOL-5-YL)BUTOXY)QUINOLINE-2,3(1H,4H)-DIONE
6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butyloxy)-3,4-dihydroquinolin-2(1H)-one
6-[4-(1-Cyclohexyl-5-tetrazolyl)butoxy]-1,2,3,4- tetrahydro-2-oxoquinolinone
Solubility of 6-[4-(1-cyclohexyltetrazol-5-yl)butoxy]-3,4-dihydro-1H-quinolin-2-one
The solubility of the compound 6-[4-(1-cyclohexyltetrazol-5-yl)butoxy]-3,4-dihydro-1H-quinolin-2-one (C20H33N5O3) can be complex and is influenced by various factors. Here are some key points to consider:
In conclusion, the solubility characteristics of this compound highlight its potential applications and limitations in various formulations, with an emphasis on solvent choice and temperature management likely affecting its use in practical applications.